Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

08 nov. 2016 08h00 HE | Source: Progenics Pharmaceuticals

Progenics Pharmaceuticals to Present at Upcoming Investor Conferences

NEW YORK, Nov. 08, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer,...
07 nov. 2016 07h55 HE | Source: Progenics Pharmaceuticals

Progenics Pharmaceuticals Announces Third Quarter 2016 Financial Results and Business Update

Received $50 Million Milestone Payment from Valeant Related to U.S. Approval of RELISTOR® TabletsCommercial Launch of RELISTOR® Tablets in September 2016On November 4th, Monetized Portion of...
07 nov. 2016 07h45 HE | Source: Progenics Pharmaceuticals

Progenics Announces $50 Million RELISTOR® Royalty-Backed Financing

NEW YORK, Nov. 07, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer,...
24 oct. 2016 08h30 HE | Source: Progenics Pharmaceuticals

Progenics Pharmaceuticals Sets Third Quarter 2016 Financial Results Call for November 7

NEW YORK, Oct. 24, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc., (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer,...
21 oct. 2016 08h30 HE | Source: Progenics Pharmaceuticals

Progenics Pharmaceuticals to Present at the 23rd Annual Prostate Cancer Foundation Scientific Retreat

NEW YORK, Oct. 21, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer,...
07 sept. 2016 08h30 HE | Source: Progenics Pharmaceuticals

Progenics Pharmaceuticals Announces Appointment of Bryce V. Tenbarge as Vice President of Commercial

NEW YORK, Sept. 07, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating...
02 sept. 2016 08h30 HE | Source: Progenics Pharmaceuticals

Progenics Pharmaceuticals to Present at the 23rd Annual NewsMakers in the Biotech Industry Conference

NEW YORK, Sept. 02, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating...
04 août 2016 07h30 HE | Source: Progenics Pharmaceuticals

Progenics Pharmaceuticals Announces Second Quarter 2016 Financial and Business Results

On July 19, the Company Announced FDA Approval of RELISTOR® Tablets, Triggering a $50 Million Milestone Ultra-Orphan Radiotherapeutic Candidate AZEDRA® Registrational Trial Topline Results...
26 juil. 2016 08h30 HE | Source: Progenics Pharmaceuticals

Progenics Receives $50 Million Milestone Payment Following FDA Approval of RELISTOR® Tablets for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-cancer Pain

TARRYTOWN, N.Y., July 26, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) announced today that it has received a $50 million milestone payment from its worldwide...
22 juil. 2016 08h30 HE | Source: Progenics Pharmaceuticals

Progenics Pharmaceuticals Sets Second Quarter 2016 Financial Results Call for August 4

TARRYTOWN, N.Y., July 22, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc., (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating...

Page précédente